Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REINA: NHS-IL12, Bintrafusp Alfa, and Radiation in Metastatic Breast Cancer
NCT04756505Phase 1Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2021
- Primary completion
- Feb 2022
- Modality
- Immunomodulatory ADCs, Cytokines & Interferons, Engineered Antibody Formats
01
Overview
Phase 1, open-label trial of NHS-IL-12 in breast cancer and Hormone-Receptor-Positive Breast Cancer, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Incidence of adverse events. Planned start Mar 2021; status: withdrawn.
02
Drugs
NHS-IL-12
03
Conditions
breast cancerHormone-Receptor-Positive Breast Cancer
Beyond the preview
Go deeper on NCT04756505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04756505.